Drug Type AAV based gene therapy |
Synonyms recombinant adeno-associated virus vector that contains a bioengineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of alpha-galactosidase A |
Target |
Action stimulants |
Mechanism GLA stimulants(α-Galactosidase stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fabry Disease | Preclinical | United States | 11 Aug 2023 |